Cryo-Save Group N.V. (CRYO) 0.4000 $CRYO
American CryoStem Enters Into Definitive Term Sheet With Health Innovative Technology Corporation Limited
GlobeNewswire - Wed Jul 02, 8:57AM CDT
American CryoStem Corporation (OTCQB:CRYO), a leading strategic developer, marketer and global licensor of patented adipose tissue-based cellular technologies for the Regenerative and Personalized Medicine industries, today announced that it has made a major step in establishing a global footprint for its cellular technology and laboratory processing platform by entering into an agreement to license its ATGRAFT(TM) adipose tissue (fat) processing and storage technologies with Health Innovative Technology Corporation Limited (HIT), a Hong Kong corporation. HIT currently operates a cellular processing and banking platform and a chain of medical centers, offering comprehensive healthcare solutions to clients in Hong Kong.
American CryoStem Announces Agreement With the nanoRANCH Division of UHV Technologies for Cancer Research Utilizing ATCELL(TM)
GlobeNewswire - Wed Jun 18, 9:17AM CDT
American CryoStem Corporation (OTCQB:CRYO), a leading strategic developer, marketer and global licensor of patented adipose tissue-based cellular technologies for the Regenerative and Personalized Medicine industries, today announced that the Company has entered into initial agreements with the nanoRANCH Division of UHV Technologies, Inc. ("nanoRANCH"
for the development of methods for the delivery of therapeutics and drugs focused upon cancer treatments utilizing adipose derived adult stem cells. The Company will be working with Dan Dimitrijevich, PhD to create new treatment delivery methods utilizing a combination of nanoRANCH unique technology and CRYO's clinically processed ATCELLs(TM).
Rent-A-Center, Inc. Announces Fourth Quarter and Year End 2013 Earnings Call and Webcast
GlobeNewswire - Wed Jan 15, 11:16AM CST
Rent-A-Center, Inc. (Nasdaq:RCII) today announced it will host a conference call on Tuesday, January 28, at 10:45 a.m. ET to discuss fourth-quarter results slated for release following the market's close on January 27. Live audio of the conference call will be available on the company's investor relations website at http://investor.rentacenter.com. A replay will be available beginning January 28 at 1:45 p.m. ET.
Best's Rating Notification - Cincinnati Life Insurance Company
Rating Division - AMBest - Thu Dec 19, 1:14PM CST
A.M. Best Company has made the following rating update:
American Cryostem Granted Interlinked an Exclusive Interview During Recent FSXinterlinked Investment Conference
PRWeb - Tue Aug 27, 3:38AM CDT
At the recent FSXinterlinked Investment Conference, held at the Ritz Carloton in Fort Lauderdale, Florida, American Cryostem's Chairman and CEO, John Arnone, granted an exclusive interview for the FSXinterlinked channel on InterlinkedTV.
American CryoStem Granted IRB Approval for Adipose Derived Stem Cell Processing Protocols
GlobeNewswire - Wed Jul 10, 7:30AM CDT
American CryoStem Corporation (OTCQB:CRYO), a leading strategic developer, marketer and global licensor of patented adipose tissue-based cellular technologies for the Regenerative and Personalized Medicine industries, today announced that its protocols for the processing of Stromal Vascular Fraction (SVF) and culturing of mesenchymal stem cells from autologous adipose tissue have been approved by the Institutional Review Board (IRB) of the International Cell Surgical Society (ICSS).
American CryoStem to Present at OneMedForumNY 2013
GlobeNewswire - Wed Jun 26, 8:35AM CDT
American CryoStem Corporation (OTCQB:CRYO), a leading strategic developer, marketer and global licensor of patented adipose tissue-based cellular technologies for the Regenerative and Personalized Medicine industries, today announced that the Company has been invited to present at OneMedForumNY 2013 to be held at the Metropolitan Club in New York City, June 26-27, 2013.
Under-valued Stem Cell Innovator Targets Growing Markets
ACCESSWIRE - Wed Jun 26, 8:00AM CDT
American CryoStem (CRYO) Targets Growing End Markets
American CryoStem Welcomes Noted Cryopreservation Expert, Dr. Dayong Gao, to Medical & Scientific Advisory Board
GlobeNewswire - Mon Jun 24, 7:30AM CDT
American CryoStem Corporation (OTCQB:CRYO), a leading strategic developer, marketer and global licensor of patented adipose tissue-based cellular technologies for the Regenerative and Personalized Medicine industries, today announced that Dayong Gao, Ph.D. has been appointed to the Company's Medical and Scientific Advisory Board.
Fat Cells Lending to New Treatments in Brain Cancer
ACCESSWIRE - Thu Jun 13, 12:30PM CDT
Regenerative medicines hold incredible potential for new, more potent therapeutics to arrive in the future for a broad spectrum of diseases and conditions. As the industry in general is growing, more possibilities are emerging seemingly on a daily basis as research uncovers new ways to use stem cells to potentially combat deadly diseases like cancer where many patients have little to no hope with today's standards of care.
American CryoStem to Present at National Investment Banking Association's 126th Investment Conference
GlobeNewswire - Tue Jun 04, 7:30AM CDT
American CryoStem Corporation (OTCQB:CRYO), a leading strategic developer, marketer and global licensor of patented adipose tissue-based cellular technologies for the Regenerative and Personalized Medicine industries, today announced that the Company has been invited to present at the National Investment Banking Association's (NIBA) 126 Investment Conference to be held in New York City, June 17-19, 2013.
Investment Ideas in the Expanding Wound Care Market
ACCESSWIRE-TNW - Fri May 17, 10:55AM CDT
Investing in Wound Care's Real Growth Drivers
American CryoStem Partners with Rutgers for Novel Wound Care Product
ACCESSWIRE-TNW - Tue May 14, 11:01AM CDT
Regenerative medicine is constantly discovering new inroads to potential therapies utilizing adult stem cells for a variety of life threatening or debilitating conditions and diseases. Progress has accelerated in the past few years, fueled in part by President Obama's 2009 Executive Order 13505 that "removed barriers" in responsible research which has opened doors to examination of new ways of thinking. It has also aided in the emergence of research in the area of adipose (fat)-based stem cell therapy, which could prove to be a major breakthrough in regenerative medicine. Not only has early research at Johns Hopkins suggested the possibility of superior efficacy with Adipose-Derived Stem Cells, or ADSCs, in the treatment of glioblastoma (a severe form of brain cancer), but ADSCs are easily harvested, meaning that they could become a standard as the most reliable and abundant source of stem cells for research, cultures and therapeutic processes.
American CryoStem to Collaborate With Rutgers University on Adipose-Derived Stem Cell Research
GlobeNewswire - Tue May 14, 7:30AM CDT
American CryoStem Corporation (OTCQB:CRYO), a leading strategic developer, marketer and global licensor of patented adipose tissue-based and cellular technologies for the Regenerative and Personalized Medicine industries, today announced that it has entered into Material Transfer Agreements with three leading research scientists at Rutgers, The State University of New Jersey, distinguished as one of the world's premier universities for stem cell research and training.
The Beauty of American CryoStem Now and in the Future
ACCESSWIRE-TNW - Thu May 09, 1:12PM CDT
"What can I do with my unwanted body fat?" That is a question that is posed by American CryoStem (OTCQB: CRYO) on the home page of its website. There are plenty of finite resources in the world, but let's face it, body fat certainly isn't one of them. A little due diligence reveals the company's answer to that question, but a more discerning examination uncovers the true growth potential of American CryoStem from an immediate, mid-term and long-term perspective.
Use Your Own Stem Cells to Combat Aging Skin
ACCESSWIRE-TNW - Tue Apr 30, 5:12PM CDT
American Cryostem (OTCQB: CRYO) is a pioneer in the fields of regenerative and personalized medicine. Their multi-faceted business model involves the patented collection and storage of adipose-derived regenerative cells (ADRC's). The fat that is collected from the patient's own body can be used in cosmetic procedures like breast and buttock enhancements, which alone is a large market opportunity. However, a more intriguing proposition lies in the world of autologous, stem-cell based cosmetics treatments designed to combat the effects of aging on skin.
American CryoStem Marks Major Global Expansion Milestone: Receives First International Shipment of Adipose Tissue for Processing and Cryo-Storage From Hong Kong
GlobeNewswire - Tue Apr 23, 9:45AM CDT
American CryoStem Corporation (OTCQB:CRYO), a leading strategic developer, marketer and global licensor of patented adipose tissue-based cellular technologies for the Regenerative and Personalized Medicine industries, today announced receipt of its first commercial international shipment of adipose tissue for processing and long term cryo-storage.
Adipose Derived Stem Cells Providing a Bridge to the Future of Regenerative Medicine
ACCESSWIRE-TNW - Thu Apr 18, 8:54AM CDT
Regenerative medicines are finally coming into their own as validated therapies for treatment of a wide spectrum of conditions and diseases. Years of research are now behind the industry and naysayers have been silenced with compilations of data demonstrating the use of stem cells to help the body heal itself. Of course, regenerative medicine is still relatively young and a moving target with new discoveries popping up and then being reinforced. A case in point is the recent work of Johns Hopkins University School of Medicine showing that mesenchymal stem cells derived from adipose (fat) tissue might be far more efficient in the treatment of glioblastoma, the most common form of brain cancer, than those derived from bone marrow, as scientists first thought. Cells derived from fat tissue can obviously be gathered in a far less invasive - and less expensive - manner.
American CryoStem to Exhibit at The Aesthetic Meeting
GlobeNewswire - Thu Apr 11, 7:30AM CDT
American CryoStem Corporation (OTCQB:CRYO), a leading biotech company in the field of Regenerative Medicine, today announced that the Company is scheduled to exhibit at The Aesthetic Meeting 2013, held this week, April 11-16 in New York City, at the Jacob Javits Convention Center. The Company will be showcasing its latest adipose tissue (fat) collection, processing and storage service, ATGRAFT(TM) and complimentary personalized skin care products. With one liposuction, ATGRAFT(TM) is a complete fat tissue storage solution for physicians to perform layered fat transfers and provides patients additional opportunities to use their stored fat tissue to create personalized skin care products or clinically processed stem cells for use in Regenerative Medicine treatments.
American CryoStem Corporation Engages Hanover Elite as Investor and Public Relations Counsel of Record
GlobeNewswire - Thu Mar 14, 8:47AM CDT
American CryoStem Corporation (OTCQB:CRYO), a leading biotech company in the field of Regenerative Medicine, today announced that it has named Hanover|Elite as the Company's Investor and Public Relations counsel of record.
American CryoStem Enters Into Definitive Term Sheet With Health Innovative Technology Corporation Limited
GlobeNewswire - Wed Jul 02, 8:57AM CDT
American CryoStem Corporation (OTCQB:CRYO), a leading strategic developer, marketer and global licensor of patented adipose tissue-based cellular technologies for the Regenerative and Personalized Medicine industries, today announced that it has made a major step in establishing a global footprint for its cellular technology and laboratory processing platform by entering into an agreement to license its ATGRAFT(TM) adipose tissue (fat) processing and storage technologies with Health Innovative Technology Corporation Limited (HIT), a Hong Kong corporation. HIT currently operates a cellular processing and banking platform and a chain of medical centers, offering comprehensive healthcare solutions to clients in Hong Kong.
American CryoStem Announces Agreement With the nanoRANCH Division of UHV Technologies for Cancer Research Utilizing ATCELL(TM)
GlobeNewswire - Wed Jun 18, 9:17AM CDT
American CryoStem Corporation (OTCQB:CRYO), a leading strategic developer, marketer and global licensor of patented adipose tissue-based cellular technologies for the Regenerative and Personalized Medicine industries, today announced that the Company has entered into initial agreements with the nanoRANCH Division of UHV Technologies, Inc. ("nanoRANCH"
for the development of methods for the delivery of therapeutics and drugs focused upon cancer treatments utilizing adipose derived adult stem cells. The Company will be working with Dan Dimitrijevich, PhD to create new treatment delivery methods utilizing a combination of nanoRANCH unique technology and CRYO's clinically processed ATCELLs(TM). Rent-A-Center, Inc. Announces Fourth Quarter and Year End 2013 Earnings Call and Webcast
GlobeNewswire - Wed Jan 15, 11:16AM CST
Rent-A-Center, Inc. (Nasdaq:RCII) today announced it will host a conference call on Tuesday, January 28, at 10:45 a.m. ET to discuss fourth-quarter results slated for release following the market's close on January 27. Live audio of the conference call will be available on the company's investor relations website at http://investor.rentacenter.com. A replay will be available beginning January 28 at 1:45 p.m. ET.
Best's Rating Notification - Cincinnati Life Insurance Company
Rating Division - AMBest - Thu Dec 19, 1:14PM CST
A.M. Best Company has made the following rating update:
American Cryostem Granted Interlinked an Exclusive Interview During Recent FSXinterlinked Investment Conference
PRWeb - Tue Aug 27, 3:38AM CDT
At the recent FSXinterlinked Investment Conference, held at the Ritz Carloton in Fort Lauderdale, Florida, American Cryostem's Chairman and CEO, John Arnone, granted an exclusive interview for the FSXinterlinked channel on InterlinkedTV.
American CryoStem Granted IRB Approval for Adipose Derived Stem Cell Processing Protocols
GlobeNewswire - Wed Jul 10, 7:30AM CDT
American CryoStem Corporation (OTCQB:CRYO), a leading strategic developer, marketer and global licensor of patented adipose tissue-based cellular technologies for the Regenerative and Personalized Medicine industries, today announced that its protocols for the processing of Stromal Vascular Fraction (SVF) and culturing of mesenchymal stem cells from autologous adipose tissue have been approved by the Institutional Review Board (IRB) of the International Cell Surgical Society (ICSS).
American CryoStem to Present at OneMedForumNY 2013
GlobeNewswire - Wed Jun 26, 8:35AM CDT
American CryoStem Corporation (OTCQB:CRYO), a leading strategic developer, marketer and global licensor of patented adipose tissue-based cellular technologies for the Regenerative and Personalized Medicine industries, today announced that the Company has been invited to present at OneMedForumNY 2013 to be held at the Metropolitan Club in New York City, June 26-27, 2013.
Under-valued Stem Cell Innovator Targets Growing Markets
ACCESSWIRE - Wed Jun 26, 8:00AM CDT
American CryoStem (CRYO) Targets Growing End Markets
American CryoStem Welcomes Noted Cryopreservation Expert, Dr. Dayong Gao, to Medical & Scientific Advisory Board
GlobeNewswire - Mon Jun 24, 7:30AM CDT
American CryoStem Corporation (OTCQB:CRYO), a leading strategic developer, marketer and global licensor of patented adipose tissue-based cellular technologies for the Regenerative and Personalized Medicine industries, today announced that Dayong Gao, Ph.D. has been appointed to the Company's Medical and Scientific Advisory Board.
Fat Cells Lending to New Treatments in Brain Cancer
ACCESSWIRE - Thu Jun 13, 12:30PM CDT
Regenerative medicines hold incredible potential for new, more potent therapeutics to arrive in the future for a broad spectrum of diseases and conditions. As the industry in general is growing, more possibilities are emerging seemingly on a daily basis as research uncovers new ways to use stem cells to potentially combat deadly diseases like cancer where many patients have little to no hope with today's standards of care.
American CryoStem to Present at National Investment Banking Association's 126th Investment Conference
GlobeNewswire - Tue Jun 04, 7:30AM CDT
American CryoStem Corporation (OTCQB:CRYO), a leading strategic developer, marketer and global licensor of patented adipose tissue-based cellular technologies for the Regenerative and Personalized Medicine industries, today announced that the Company has been invited to present at the National Investment Banking Association's (NIBA) 126 Investment Conference to be held in New York City, June 17-19, 2013.
Investment Ideas in the Expanding Wound Care Market
ACCESSWIRE-TNW - Fri May 17, 10:55AM CDT
Investing in Wound Care's Real Growth Drivers
American CryoStem Partners with Rutgers for Novel Wound Care Product
ACCESSWIRE-TNW - Tue May 14, 11:01AM CDT
Regenerative medicine is constantly discovering new inroads to potential therapies utilizing adult stem cells for a variety of life threatening or debilitating conditions and diseases. Progress has accelerated in the past few years, fueled in part by President Obama's 2009 Executive Order 13505 that "removed barriers" in responsible research which has opened doors to examination of new ways of thinking. It has also aided in the emergence of research in the area of adipose (fat)-based stem cell therapy, which could prove to be a major breakthrough in regenerative medicine. Not only has early research at Johns Hopkins suggested the possibility of superior efficacy with Adipose-Derived Stem Cells, or ADSCs, in the treatment of glioblastoma (a severe form of brain cancer), but ADSCs are easily harvested, meaning that they could become a standard as the most reliable and abundant source of stem cells for research, cultures and therapeutic processes.
American CryoStem to Collaborate With Rutgers University on Adipose-Derived Stem Cell Research
GlobeNewswire - Tue May 14, 7:30AM CDT
American CryoStem Corporation (OTCQB:CRYO), a leading strategic developer, marketer and global licensor of patented adipose tissue-based and cellular technologies for the Regenerative and Personalized Medicine industries, today announced that it has entered into Material Transfer Agreements with three leading research scientists at Rutgers, The State University of New Jersey, distinguished as one of the world's premier universities for stem cell research and training.
The Beauty of American CryoStem Now and in the Future
ACCESSWIRE-TNW - Thu May 09, 1:12PM CDT
"What can I do with my unwanted body fat?" That is a question that is posed by American CryoStem (OTCQB: CRYO) on the home page of its website. There are plenty of finite resources in the world, but let's face it, body fat certainly isn't one of them. A little due diligence reveals the company's answer to that question, but a more discerning examination uncovers the true growth potential of American CryoStem from an immediate, mid-term and long-term perspective.
Use Your Own Stem Cells to Combat Aging Skin
ACCESSWIRE-TNW - Tue Apr 30, 5:12PM CDT
American Cryostem (OTCQB: CRYO) is a pioneer in the fields of regenerative and personalized medicine. Their multi-faceted business model involves the patented collection and storage of adipose-derived regenerative cells (ADRC's). The fat that is collected from the patient's own body can be used in cosmetic procedures like breast and buttock enhancements, which alone is a large market opportunity. However, a more intriguing proposition lies in the world of autologous, stem-cell based cosmetics treatments designed to combat the effects of aging on skin.
American CryoStem Marks Major Global Expansion Milestone: Receives First International Shipment of Adipose Tissue for Processing and Cryo-Storage From Hong Kong
GlobeNewswire - Tue Apr 23, 9:45AM CDT
American CryoStem Corporation (OTCQB:CRYO), a leading strategic developer, marketer and global licensor of patented adipose tissue-based cellular technologies for the Regenerative and Personalized Medicine industries, today announced receipt of its first commercial international shipment of adipose tissue for processing and long term cryo-storage.
Adipose Derived Stem Cells Providing a Bridge to the Future of Regenerative Medicine
ACCESSWIRE-TNW - Thu Apr 18, 8:54AM CDT
Regenerative medicines are finally coming into their own as validated therapies for treatment of a wide spectrum of conditions and diseases. Years of research are now behind the industry and naysayers have been silenced with compilations of data demonstrating the use of stem cells to help the body heal itself. Of course, regenerative medicine is still relatively young and a moving target with new discoveries popping up and then being reinforced. A case in point is the recent work of Johns Hopkins University School of Medicine showing that mesenchymal stem cells derived from adipose (fat) tissue might be far more efficient in the treatment of glioblastoma, the most common form of brain cancer, than those derived from bone marrow, as scientists first thought. Cells derived from fat tissue can obviously be gathered in a far less invasive - and less expensive - manner.
American CryoStem to Exhibit at The Aesthetic Meeting
GlobeNewswire - Thu Apr 11, 7:30AM CDT
American CryoStem Corporation (OTCQB:CRYO), a leading biotech company in the field of Regenerative Medicine, today announced that the Company is scheduled to exhibit at The Aesthetic Meeting 2013, held this week, April 11-16 in New York City, at the Jacob Javits Convention Center. The Company will be showcasing its latest adipose tissue (fat) collection, processing and storage service, ATGRAFT(TM) and complimentary personalized skin care products. With one liposuction, ATGRAFT(TM) is a complete fat tissue storage solution for physicians to perform layered fat transfers and provides patients additional opportunities to use their stored fat tissue to create personalized skin care products or clinically processed stem cells for use in Regenerative Medicine treatments.
American CryoStem Corporation Engages Hanover Elite as Investor and Public Relations Counsel of Record
GlobeNewswire - Thu Mar 14, 8:47AM CDT
American CryoStem Corporation (OTCQB:CRYO), a leading biotech company in the field of Regenerative Medicine, today announced that it has named Hanover|Elite as the Company's Investor and Public Relations counsel of record.
